138 related articles for article (PubMed ID: 19299547)
1. Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: an independent cancer biomarker.
Korbakis D; Gregorakis AK; Scorilas A
Clin Chem; 2009 May; 55(5):904-13. PubMed ID: 19299547
[TBL] [Abstract][Full Text] [Related]
2. Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance.
Avgeris M; Stravodimos K; Scorilas A
Prostate; 2011 Dec; 71(16):1780-9. PubMed ID: 21520157
[TBL] [Abstract][Full Text] [Related]
3. Real-time quantitative RT-PCR assessment of PIM-1 and hK2 mRNA expression in benign prostate hyperplasia and prostate cancer.
He HC; Bi XC; Zheng ZW; Dai QS; Han ZD; Liang YX; Ye YK; Zeng GH; Zhu G; Zhong WD
Med Oncol; 2009; 26(3):303-8. PubMed ID: 19003546
[TBL] [Abstract][Full Text] [Related]
4. Expression of kallikrein-related peptidase 7 is decreased in prostate cancer.
Zhang CY; Zhu Y; Rui WB; Dai J; Shen ZJ
Asian J Androl; 2015; 17(1):106-10. PubMed ID: 25219913
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues.
Yousef GM; Scorilas A; Chang A; Rendl L; Diamandis M; Jung K; Diamandis EP
Prostate; 2002 May; 51(2):126-32. PubMed ID: 11948967
[TBL] [Abstract][Full Text] [Related]
6. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
7. MiR-139-5p is Increased in the Peripheral Blood of Patients with Prostate Cancer.
Pang C; Liu M; Fang W; Guo J; Zhang Z; Wu P; Zhang Y; Wang J
Cell Physiol Biochem; 2016; 39(3):1111-7. PubMed ID: 27562849
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer.
Kurlender L; Yousef GM; Memari N; Robb JD; Michael IP; Borgoño C; Katsaros D; Stephan C; Jung K; Diamandis EP
Tumour Biol; 2004; 25(3):149-56. PubMed ID: 15361712
[TBL] [Abstract][Full Text] [Related]
9. mRNA expression analysis of human kallikrein 11 (KLK11) may be useful in the discrimination of benign prostatic hyperplasia from prostate cancer after needle prostate biopsy.
Scorilas A; Gregorakis AK
Biol Chem; 2006 Jun; 387(6):789-93. PubMed ID: 16800741
[TBL] [Abstract][Full Text] [Related]
10. Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer.
Avgeris M; Koutalellis G; Fragoulis EG; Scorilas A
Clin Biochem; 2008 Oct; 41(14-15):1140-9. PubMed ID: 18586020
[TBL] [Abstract][Full Text] [Related]
11. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
[TBL] [Abstract][Full Text] [Related]
12. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
[TBL] [Abstract][Full Text] [Related]
13. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
14. Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer.
Yousef GM; Scorilas A; Kyriakopoulou LG; Rendl L; Diamandis M; Ponzone R; Biglia N; Giai M; Roagna R; Sismondi P; Diamandis EP
Clin Chem; 2002 Aug; 48(8):1241-50. PubMed ID: 12142380
[TBL] [Abstract][Full Text] [Related]
15. Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression.
Mavridis K; Stravodimos K; Scorilas A
Prostate; 2013 Aug; 73(11):1191-201. PubMed ID: 23620432
[TBL] [Abstract][Full Text] [Related]
16. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.
Zhong W; Peng J; He H; Wu D; Han Z; Bi X; Dai Q
Clin Invest Med; 2008; 31(1):E8-E15. PubMed ID: 18312749
[TBL] [Abstract][Full Text] [Related]
17. Uncovering the clinical impact of kallikrein-related peptidase 5 (KLK5) mRNA expression in the colorectal adenoma-carcinoma sequence.
Papachristopoulou G; Malachias A; Devetzi M; Kamouza E; Scorilas A; Xynopoulos D; Talieri M
Clin Chem Lab Med; 2019 Jul; 57(8):1251-1260. PubMed ID: 30759066
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor of DNA binding-1 overexpression in prostate cancer: relevance to tumor differentiation.
Yu X; Xu X; Han B; Zhou R
Pathol Oncol Res; 2009 Mar; 15(1):91-6. PubMed ID: 18752043
[TBL] [Abstract][Full Text] [Related]
19. Real-time RT-PCR for the measurement of prostate-specific antigen mRNA expression in benign hyperplasia and adenocarcinoma of prostate.
Gelmini S; Tricarico C; Petrone L; Forti G; Amorosi A; Dedola GL; Serio M; Pazzagli M; Orlando C
Clin Chem Lab Med; 2003 Mar; 41(3):261-5. PubMed ID: 12705330
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
